-
NovAliX expands cryo-electron microscopy (cryo-EM) capabilities for drug development offering
Expansion includes acquisition of novel, high-resolution cryo-electron microscope – with micro electron diffraction (microED) capabilities for solving protein and small molecule structures NovAliX will further develop cryo-EM service offerings for pharmaceutical industry NovAliX, a drug discovery-focused Contract Research Organization (CRO), today announces the expansion of its cryogenic electron microscopy (cryo-EM) technology capability. NovAliX will benefit from the implementation at its premises of Thermo Fisher Scientific’s high-resolution microscope, the Thermo Scientific Glacios Cryo-TEM, with additional micro-electron diffraction (microED) capabilities for solving protein and small molecule structures using nanoscale crystals. This enables NovAliX to integrate an upgrade of a key technology to complement its existing biophysics capabilities, which will improve the success…
-
NovAliX appoints Dr. Jerome Guillemont as head of drug discovery, alongside two new directors
Founded in 2002 and based in Strasbourg, France, NovAliX is a drug discovery-focused CRO with several unique technologies. It employs 200 researchers, with capabilities combining chemistry and biophysics. NovAliX offers its clients original collaborative models and extensive services within the framework of research programs dedicated to drug discovery. Its ambition is to continue its development by both strengthening its internationalization and extending and integrating the new capabilities essential to the success of its clients‘ therapeutic research projects into its technologies and base of expertise. www.novalix.comDuring his accomplished career, Dr. Guillemont has discovered successful drug candidates in a wide range of therapeutic areas, working on antibacterials, gastroenterology and virology With this latest…
